Edition:
United Kingdom

Profile: Arcturus Therapeutics Ltd (ARCT.OQ)

ARCT.OQ on NASDAQ Stock Exchange Global Market

6.07USD
17 Jun 2019
Change (% chg)

$-0.28 (-4.41%)
Prev Close
$6.35
Open
$6.34
Day's High
$6.69
Day's Low
$6.07
Volume
4,630
Avg. Vol
12,058
52-wk High
$10.00
52-wk Low
$4.11

Arcturus Therapeutics Ltd., incorporated on February 7, 2008, is a ribonucleic acid (RNA) medicines company. The Company owns Lipid-enabled and Unlocked Nucleomonomer Agent modified RNA (LUNAR) lipid-mediated delivery and Unlocked Nucleomonomer Agent (UNA) technology, including UNA Oligomers. The Company’s diverse pipeline of RNA therapeutics includes programs pursuing rare diseases, Hepatitis B, non-alcoholic steatohepatitis (NASH), cystic fibrosis and vaccines. The Company’s versatile RNA therapeutics platforms can be applied toward multiple types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA and gene editing therapeutics. The Company's UNA technology can be used to target individual genes in the human genome, as well as viral genes, and other species for therapeutic purposes.

The Company's technology LUNAR is a multi-component drug delivery system that is versatile and with is a library of over 150 lipids, diverse. The Company's second technology is an oligonucleotide chemistry technology called Unlocked Nucleomonomer Agent (UNA). The Company's UNA can be used to reduce off-target effects and increase duration of action in siRNA medicines. The Company's platform includes LUNAR-HBV, LUNAR-NASH and LUNAR-GSD3. LUNAR-HBV is a nucleic acid medicine to fight HBV without the same side effect issues that plague existing therapies. LUNAR-NASH Nonalcoholic steatohepatitis (NASH) is the serious form of nonalcoholic fatty liver disease. The Company develops RNA-based therapeutic candidates to treat NASH. The Company's current program activities include lead candidate identification and duration of action studies in various models of disease. LUNAR-GSD3 Glycogen Storage Disease type III (GSD3) is a genetic disease, develops mRNA medicines to replace the defective Acute Granulocytic Leukemia (AGL) gene product and allow cells to breakdown glycogen using normal pathways.

Company Address

Arcturus Therapeutics Ltd

10628 Science Center Dr Ste 200
SAN DIEGO   CA   92121-1128
P: +1858.9002660
F: +9727.22204664

Company Web Links